Pharvaris (PHVS) Is Up 11.3% After Deucrictibant Shows 92% Drop in HAE Attacks and Reports Q3 Loss [Yahoo! Finance]
Pharvaris N.V. - Ordinary Shares (PHVS)
Company Research
Source: Yahoo! Finance
hereditary angioedema attacks over nearly three years, while also reporting a net loss of €37.14 million for the third quarter of 2025. The clinical results, along with a validated plasma kinin biomarker assay, have added visibility to upcoming pivotal Phase 3 trial timelines for deucrictibant in both prophylactic and on-demand treatment settings. We'll now explore how the compelling long-term efficacy data for deucrictibant shapes Pharvaris's investment narrative and outlook. We've found 15 US stocks that are forecast to pay a dividend yield of over 6% next year . See the full list for free. What Is Pharvaris' Investment Narrative? To be a Pharvaris shareholder, you need to believe in the ability of its pipeline, especially deucrictibant, to drive future commercial prospects in hereditary angioedema treatment, overcoming unprofitability, and navigating the capital demands of late-stage drug development. The recent release of the long-term efficacy data for deucrictibant at
Show less
Read more
Impact Snapshot
Event Time:
PHVS
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
PHVS alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
PHVS alerts
High impacting Pharvaris N.V. - Ordinary Shares news events
Weekly update
A roundup of the hottest topics
PHVS
News
- Pharvaris (NASDAQ:PHVS) had its "buy" rating reaffirmed by analysts at Guggenheim.MarketBeat
- Pharvaris (NASDAQ:PHVS) had its "outperform" rating reaffirmed by analysts at Oppenheimer Holdings, Inc..MarketBeat
- Pharvaris (NASDAQ:PHVS) had its price target raised by analysts at Bank of America Corporation from $27.00 to $30.00. They now have a "neutral" rating on the stock.MarketBeat
- Pharvaris (PHVS) Is Up 5.9% After Phase 3 RAPIDe-3 Win - Has The Bull Case Changed? [Yahoo! Finance]Yahoo! Finance
- Pharvaris (NASDAQ:PHVS) had its "overweight" rating reaffirmed by analysts at Morgan Stanley.MarketBeat
PHVS
Earnings
- 11/12/25 - Beat
PHVS
Sec Filings
- 12/4/25 - Form 144
- 12/3/25 - Form 144
- 12/3/25 - Form 144
- PHVS's page on the SEC website